Eyenovia Completes Public Offering
Eyenovia, Inc. (NASDAQ: EYEN), a prominent company in ophthalmic technology, has successfully concluded its public offering. This offering involved the sale of 12,850,000 shares of common stock, priced at $0.40 each, resulting in gross proceeds of around $5.14 million for the company.
How the Proceeds Will Be Used
The capital raised from this public offering will be directed towards several important initiatives. Eyenovia plans to utilize the net proceeds primarily to support the commercialization of its innovative products, Mydcombi and Clobetasol Propionate. Additionally, the funds will help complete the CHAPERONE pediatric myopia clinical study. The remaining capital will also address general corporate needs, including repaying a portion of Eyenovia's existing debt.
Placement Agent's Role
Dawson James Securities, Inc. acted as the placement agent for this offering, overseeing the sales and distribution process to ensure its success.
Compliance with Regulations
The securities offered by Eyenovia complied with its previously filed shelf registration statement on Form S-3, which was approved by the Securities and Exchange Commission. Details of the offering were provided through a prospectus supplement along with a base prospectus.
Accessing Offering Documents
Those interested can find the prospectus supplement and the base prospectus on the SEC's website or by reaching out to Dawson James Securities for additional copies.
About Eyenovia, Inc.
Eyenovia, Inc. is a leader in ophthalmic technology, dedicated to commercializing Mydcombi™, an ophthalmic spray designed for mydriasis, and Clobetasol Propionate Ophthalmic Suspension, which is used to manage inflammation and pain following surgery. The company is also working on the Optejet® device, aimed at improving drug delivery for pediatric progressive myopia, with potential for licensing in other applications.
Looking Ahead: Expertise and Vision
As Eyenovia moves forward, it is committed to maximizing shareholder value through strategic initiatives and clinical advancements. The company is focused on advancing its product pipeline and exploring new market opportunities.
Contact Information
For any inquiries, Eyenovia can be contacted through the following representatives:
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is Eyenovia's recent public offering about?
Eyenovia raised approximately $5.14 million through a public offering of 12,850,000 shares of common stock.
How will Eyenovia use the proceeds from the offering?
The funds will be used to support commercialization activities, clinical studies, and general corporate purposes.
Who acted as the placement agent for the offering?
Dawson James Securities, Inc. served as the placement agent for this public offering.
What products are associated with Eyenovia?
Eyenovia's key products include Mydcombi and Clobetasol Propionate Ophthalmic Suspension.
What is the future direction of Eyenovia?
Eyenovia is focused on advancing its product pipeline and maximizing shareholder value through strategic initiatives.
